- In January 2025, Norlase announced the commercial launch and received FDA 510(k) clearance and CE Mark for Norlase LYNX, the world’s first battery-powered, pattern scanning laser indirect ophthalmoscope. This innovation significantly enhances the ophthalmic lasers market by introducing a fully portable, untethered solution that allows surgeons to perform treatments in a wider range of clinical settings. With its integrated laser and pattern module built into a lightweight headset, along with advanced features such as wireless control and multilingual voice commands, LYNX is set to improve surgical efficiency and accessibility, driving further adoption of laser-based treatments worldwide
- In August 2024, Meridian Medical received FDA approval for its MR Q laser family, comprising the MR Q, MR Q SLT, and MR Q Supine, marking a significant advancement in the ophthalmic lasers market by expanding the availability of versatile, fully integrated Nd:YAG laser systems in the U.S.
- In February 2024, Meridian Medical AG expanded its presence in the U.S. ophthalmic lasers market with the launch of three new Microruptor (MR) Q laser models: MR Q, MR Q SLT, and MR Q Supine. This product expansion strengthens Meridian’s portfolio by offering advanced laser options tailored for diverse clinical needs, enhancing treatment versatility and reinforcing the company’s competitive position in the growing U.S. ophthalmic laser market
- In January 2024, Iridex Corporation launched its Iridex 532 and Iridex 577 laser platforms in the U.S., featuring continuous-wave and proprietary MicroPulse technology along with intuitive touchscreen controls, further strengthening its market position by offering clinicians greater flexibility and precision in laser-based eye treatments
